Spruce Biosciences (NASDAQ:SPRB) stock advanced 4.1% in pre-market trading to $64 after H.C. Wainwright reiterated its Buy rating and $150 price target, highlighting encouraging regulatory progress ahead of a planned Biologics License Application for tralesinidase alfa enzyme replacement therapy (TA-ERT).
The company recently completed two constructive pre-BLA meetings with the FDA, supporting plans to submit the therapy for Sanfilippo Syndrome Type B during the fourth quarter of 2026. Importantly, the FDA indicated that Spruce Biosciences’ proposed analytical comparability strategies for both the drug substance and finished drug product were reasonable, providing additional clarity ahead of the anticipated filing.
H.C. Wainwright maintains bullish stance
H.C. Wainwright’s latest assessment provided the main catalyst for the pre-market advance, while broader analyst sentiment towards Spruce Biosciences (NASDAQ:SPRB) also remains favourable.
The analyst community currently has a Strong Buy consensus on SPRB, with price targets ranging from $104 to $230. Guggenheim and Citizens recently lowered their respective targets following the company’s second-quarter results, but H.C. Wainwright’s decision to maintain its $150 objective signals continued confidence in the company’s regulatory timetable.
Spruce Biosciences also announced alongside its recent quarterly results that it had secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society, adding further support as the company works towards its next regulatory milestone.
Positive market conditions provide additional support
Broader market sentiment is also working in Spruce Biosciences’ favour, with the Nasdaq Composite rising 1.2% and the S&P 500 gaining 0.5%. The risk-on environment has helped support smaller biotechnology and pharmaceutical companies, adding momentum to the company-specific catalyst.
Spruce Biosciences has traded within a particularly wide 52-week range of $7 to $240, highlighting the shares’ elevated volatility and their potential sensitivity to positive regulatory developments, analyst commentary and clinical milestones.
Q4 BLA submission moves into focus
The combination of supportive FDA feedback, H.C. Wainwright’s reiterated Buy recommendation and investment from organisations focused on Sanfilippo Syndrome has strengthened sentiment around Spruce Biosciences.
Attention is now increasingly centred on the company’s planned fourth-quarter 2026 BLA submission for TA-ERT. Staying on schedule would represent an important milestone for Spruce Biosciences as it works to advance the therapy towards potential regulatory approval and commercialisation.